Journal of Neurology

, Volume 257, Issue 5, pp 856–857 | Cite as

Levodopa responsive hemidystonia associated with contralateral nigral lesion

  • Chul Hyoung Lyoo
  • Myung Sik LeeEmail author
Letter to the editors


A focal brain lesion in the basal ganglia or thalamus is frequently the cause of symptomatic hemidystonia. However, brainstem lesions may also induce dystonia with or without parkinsonism [3, 10]. Patients with such secondary dystonia respond poorly to medical treatment [1, 5]. We report a patient who had a 56-years history of levodopa responsive hemidystonia associated with a lesion in the contralateral substantia nigra.

Case report

A 63 year-old woman presented with 56 years’ history of dystonia involving the neck and the right arm and leg. Her birth and perinatal histories were unremarkable. At the age of three, she developed a severe febrile illness that was accompanied by mental change for several days. During that insult, she developed right hemiplegia, but improved over a period of 3 months. At the age of seven, she developed dystonia of the right hand and leg. The dystonia was stable until the age of 33, when she first sought medical treatment. She was treated with...


Levodopa Dystonia Substantia Nigra Levodopa Treatment Dopa Responsive Dystonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by a faculty research grant of Yonsei University College of Medicine (grant number 6-2008-0236).

Supplementary material

Supplementary material 1 (MPG 6869 kb)

Supplementary material 2 (MPG 5004 kb)


  1. 1.
    Chuang C, Fahn S, Frucht SJ (2002) The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry 72:59–67CrossRefPubMedGoogle Scholar
  2. 2.
    Grandas F, Galiano ML, Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson’s disease. J Neurol 246:1127–1133CrossRefPubMedGoogle Scholar
  3. 3.
    Loher TJ, Krauss JK (2009) Dystonia associated with pontomesencephalic lesions. Mov Disord 24:157–167CrossRefPubMedGoogle Scholar
  4. 4.
    Nygaard TG, Marsden CD, Fahn S (1991) Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 41:174–181PubMedGoogle Scholar
  5. 5.
    Pettigrew LC, Jankovic J (1985) Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry 48:650–657CrossRefPubMedGoogle Scholar
  6. 6.
    Sato K, Sumi-Ichinose C, Kaji R, Ikemoto K, Nomura T, Nagatsu I, Ichinose H, Ito M, Sako W, Nagahiro S, Graybiel AM, Goto S (2008) Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. Proc Natl Acad Sci U S A 105:12551–12556CrossRefPubMedGoogle Scholar
  7. 7.
    Savant CS, Singhal BS, Jankovic J, Khan M, Virani A (2003) Substantia nigra lesions in viral encephalitis. Mov Disord 18:213–216CrossRefPubMedGoogle Scholar
  8. 8.
    Smith Y, Villalba R (2008) Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and parkinsonian brains. Mov Disord 23(Suppl 3):S534–547CrossRefPubMedGoogle Scholar
  9. 9.
    Thanvi BR, Lo TC (2004) Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J 80:452–458CrossRefPubMedGoogle Scholar
  10. 10.
    Vidailhet M, Dupel C, Lehericy S, Remy P, Dormont D, Serdaru M, Jedynak P, Veber H, Samson Y, Marsault C, Agid Y (1999) Dopaminergic dysfunction in midbrain dystonia: anatomoclinical study using 3-dimensional magnetic resonance imaging and fluorodopa F 18 positron emission tomography. Arch Neurol 56:982–989CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of Neurology, Gangnam Severance HospitalYonsei University College of MedicineSeoulKorea

Personalised recommendations